Sangeeta Bhatia

Core Faculty
Phone: (617) 324-0221
Lab Phone: (617) 324-0610
Lab Fax: (617) 324-0740
room: 76-453
MIT address: 77 Massachusetts Ave., Cambridge, MA 02139
Administrative Assistant: Sue Kangiser
assistant phone: (617) 253-0893
assistant email:

Sangeeta Bhatia

Core Faculty


  • John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, Massachusetts Institute of Technology
  • Director, Laboratory for Multiscale Regenerative Technologies
  • Director, Marble Center for Cancer Nanomedicine, Koch Institute
  • Investigator, Howard Hughes Medical Institute


Sangeeta is a biomedical researcher, MIT professor, and biotech entrepreneur who works to adapt technologies developed in the computer industry for medical innovation. Trained as both a physician and engineer at Harvard, MIT, and Brown University, Bhatia leverages ‘tiny technologies’ of miniaturization to yield inventions such as human microlivers that model human drug metabolism and liver disease, as well as responsive nanoparticles and nanoporous materials that can be engineered to diagnose, study, and treat a variety of diseases, including cancer. She and her trainees have launched multiple biotechnology companies to improve human health. As a prolific inventor and passionate advocate for diversity in science and engineering, Bhatia has received many honors including the Lemelson-MIT Prize, known as the ‘Oscar for inventors,’ and the Heinz Medal for groundbreaking inventions and advocacy for women in STEM fields. She is a Howard Hughes Medical Institute Investigator, the Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research at MIT, and an elected member of the National Academy of Sciences, the National Academy of Engineering, the American Academy of Arts and Science, the National Academy of Inventors, and Brown University’s Board of Trustees.


  • MD, Harvard Medical School, 1999
  • Ph.D in Biomedical Engineering, Massachusetts Institute of Technology, 1997
  • M.S. in Mechanical Engineering, Massachusetts Institute of Technology
  • B.S. in Biomedical Engineering, Brown University

selected awards/societies

  • DSc (Medicine) honoris causa, University of London- Institute Cancer Research, 2019
  • Othmer Gold Medal, Science History Institute (Chemical Heritage Foundation), 2019
  • Honorary Doctorate, Utrecht University, the Netherlands
  • National Academy of Sciences, 2017
  • National Academy of Inventors, 2016
  • Heinz Award, 2015
  • National Academy of Engineering, 2015
  • Lemelson-MIT Prize, 2014
  • Massachusetts Academy of Sciences
  • Biomedical Engineering Society
  • American Institute for Medical and Biological Engineering
  • American Society for Clinical Investigation
  • David and Lucile Packard Fellowship
  • NSF Career Award
  • C. Fung Young Investigator Award of the American College of Clinical Pharmacology
  • Brown Engineering Alumni Medal
  • Merkin Fellow, Broad Institute
  • Harvard Medical School Diversity Award
  • Harvard-MIT Thomas McMahon Mentoring Award


Research Interests

Nano-based Drugs and Delivery Mechanisms

Activity-based Diagnostics

Hepatic Tissue Engineering and Disease

Our laboratory conducts research at the intersection of engineering, medicine, and biology to develop novel platforms for understanding, diagnosing, and treating human disease. Our long-term goals are to improve cellular therapies for liver disease, develop microtechnology tools to systematically study living cells, and design multifunctional nanomaterial systems which assemble and communicate to interrogate and coordinately treat cancer. We have developed technologies for interfacing living cells with synthetic systems, enabling new applications in tissue regeneration, stem cell differentiation, medical diagnostics and drug delivery. One such platform applies microfabrication technologies used in semiconductor manufacturing to organize cells of different types to produce a tissue with emergent properties. These efforts have produced human microlivers which model human drug metabolism, drug-induced liver disease, and interaction with human pathogens, thereby establishing high-throughput models that fully replicate the life cycles of hepatitis C and liver-stage human malaria, and are being used for drug testing, discovery, and tissue engineering applications. We are also involved in a multidisciplinary effort to develop nanomaterials as tools for biological studies and as multifunctional agents for cancer therapies. By bridging the unique electromagnetic properties of nanomaterials with advances in bioconjugate chemistry, photonics, and phage display we aim to develop “intelligent” systems for tumor therapy and biomolecular detection. Our interest centers around nanoparticles and nanoporous materials that can be designed to perform complex tasks such as home to a tumor, sense changes in cells and tissues, enhance imaging, recruit complementary nanoparticles and signal pathways, and trigger the release of a targeted, therapeutic payload.

Our lab philosophy also includes a strong emphasis on the professional development of our trainees, and also a commitment to promoting diversity in STEM training and research, as well as communication of science to the public.

Learn more about the work the Bhatia lab is doing by visiting their website and by watching this video: Inside the Lab: Sangeeta Bhatia, M.D., Ph.D.

Selected Publications

  • A. F. Bagley, R. Scherz-Shouval, P. A. Galie, A. Q. Zhang, J. Wyckoff, L. Whitesell, C. S. Chen, S. Lindquist, and S. N. Bhatia. “Endothelial thermotolerance impairs nanoparticle transport in tumors.” Cancer Res 75.16 (2015): 3255-67.
  • V. Ramanan†, A. Shlomai†, D. B. T. Cox†, R. E. Schwartz, E. Michailidis, A. Bhatta, D. A. Scott, F. Zhang‡, C. M. Rice‡, and S. N. Bhatia‡. “CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.” Sci Rep 5 (2015).
  • T. Danino†, A. Prindle†, G. A. Kwong, M. Skalak, H. Li, K. Allen, J. Hasty‡, and S. N. Bhatia‡. “Programmable probiotics for detection of cancer in urine.” Science Translational Medicine 7 (2015): 289ra84.
  • N. E. Reticker-Flynn and S. N. Bhatia. “Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche.” Cancer Discov 5.2 (2015): 168-81.
  • A. Shlomai†, R. E. Schwartz†, V. Ramanan†, A. Bhatta, Y. P. de Jong, S. N. Bhatia‡, and C. M. Rice‡. “Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.” Proc Natl Acad Sci USA 111.33 (2014): 12193-8.
  • S. March, S. Y. Ng, S. Velmurugan, A. Galstian, J. Shan, D. J. Logan, A. E. Carpenter, D. Thomas, B. Kim Lee Sim, M. M. Mota, S. L. Hoffman, and S. N. Bhatia. “A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax.” Cell Host Microbe 14.1 (2013): 104-115.
  • J. D. Baranski, R. R. Chaturvedi, K. R. Stevens, J. Eyckmans, B. Carvahlo, R. D. Solorzano, M. T. Yang, J.S. Miller, S. N. Bhatia, and C. S. Chen. “Geometric control of vascular networks to enhance engineered tissue integration and function.” PNAS 110 (2013): 7586-7591.
  • J. Shan, R. E. Schwartz, N. T. Ross, D. J. Logan, S. A. Duncan, T. E. North, W. Goessling, A. E. Carpenter, and S. N. Bhatia. “Identification of small molecules for human hepatocyte expansion and iPS differentiation.” Nature Chemical Biology (2013): 514-20.
  • G. A. Kwong, G. von Maltzahn, G. Murugappan, O. Abudayyeh, S. Mo, I. A. Papayannopoulos, D. Y. Sverdlov, S. B. Liu, A. D. Warren, Y. Popov, D. Schuppan, and S. N. Bhatia. “Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.” Nature Biotechnology 31 (2012): 63-70.

A full list of Professor Bhatia’s publications can be found on her website.